BREAST CANCER METASTATIC

This early-stage trial tests the safety of combining two drugs, olaparib and vorinostat, for people with breast cancer that has returned or spread. The study includes 28 adults with certain types of advanced breast cancer. The goal is to find the best dose and see if the combinat…

This early-stage trial tests a new two-part treatment for people with advanced breast cancer that has not responded to standard therapies. Participants receive a single infusion of their own engineered immune cells (CLBR001) followed by cycles of a biologic drug (ABBV-461). The m…

This study tests a combination of two drugs, sacituzumab govitecan and trastuzumab, in 28 people with HER2+ breast cancer that has spread and has been previously treated. The goal is to see if this combination can shrink tumors or slow cancer growth. Participants receive both dru…

This study screens people with HR-positive, HER2-low metastatic breast cancer who are taking a CDK4/6 inhibitor. If a blood test still finds cancer DNA after one month, they receive the targeted drug trastuzumab deruxtecan (T-DXd). The goal is to see if T-DXd can delay cancer gro…

This study aimed to collect information from routine medical care of people with a certain type of advanced breast cancer (HR+/HER2-). Researchers planned to track side effects and how well the treatment worked, without giving any new drugs or changing care. The study was withdra…

This study looks at whether simple blood tests can predict when a patient's cancer is stable, so they can skip some routine scans. About 97 women with ER-positive, HER2-negative metastatic breast cancer taking hormone therapy will give blood samples at regular checkups. Researche…

This study looks at 50 patients with HER2-positive metastatic breast cancer who have had a good response to anti-HER2 therapy for at least two years. Researchers will use a blood test called Signatera to check for tiny bits of cancer DNA. The goal is to learn if this test can hel…